310 related articles for article (PubMed ID: 28817737)
21. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
22. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
[TBL] [Abstract][Full Text] [Related]
23. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
[TBL] [Abstract][Full Text] [Related]
24. LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer.
Luo L; Tang H; Ling L; Li N; Jia X; Zhang Z; Wang X; Shi L; Yin J; Qiu N; Liu H; Song Y; Luo K; Li H; He Z; Zheng G; Xie X
Oncogene; 2018 Nov; 37(47):6166-6179. PubMed ID: 30002443
[TBL] [Abstract][Full Text] [Related]
25. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin and TRAIL enhance breast cancer stem cell death.
Yin S; Xu L; Bandyopadhyay S; Sethi S; Reddy KB
Int J Oncol; 2011 Oct; 39(4):891-8. PubMed ID: 21687939
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
28. SNAI1-mediated transcriptional regulation of epithelial-to-mesenchymal transition genes in breast cancer stem cells.
Singh D; Deshmukh RK; Das A
Cell Signal; 2021 Nov; 87():110151. PubMed ID: 34537302
[TBL] [Abstract][Full Text] [Related]
29. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M; Venkata PP; Viswanadhapalli S; Palacios B; Alejo S; Chen Y; He Y; Pratap UP; Liu J; Zou Y; Lai Z; Suzuki T; Brenner AJ; Tekmal RR; Vadlamudi RK; Sareddy GR
Breast Cancer Res Treat; 2021 Jan; 185(2):343-357. PubMed ID: 33057995
[TBL] [Abstract][Full Text] [Related]
30. Ketoplatin in triple-negative breast cancer cells MDA-MB-231: High efficacy and low toxicity, and positive impact on inflammatory microenvironment.
Ma ZY; Song XQ; Hu JJ; Wang DB; Ding XJ; Liu RP; Dai ML; Meng FY; Xu JY
Biochem Pharmacol; 2021 Jun; 188():114523. PubMed ID: 33741331
[TBL] [Abstract][Full Text] [Related]
31. Novel strategies to target chemoresistant triple-negative breast cancer.
Venkatesh J; Rishi AK; Reddy KB
Genes Cancer; 2020 Dec; 11(3-4):95-105. PubMed ID: 33488948
[TBL] [Abstract][Full Text] [Related]
32. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
33. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of ERRĪ± suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
35. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.
Teslow EA; Mitrea C; Bao B; Mohammad RM; Polin LA; Dyson G; Purrington KS; Bollig-Fischer A
Mol Oncol; 2019 Apr; 13(4):894-908. PubMed ID: 30636104
[TBL] [Abstract][Full Text] [Related]
36. Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.
Christensen AG; Ehmsen S; Terp MG; Batra R; Alcaraz N; Baumbach J; Noer JB; Moreira J; Leth-Larsen R; Larsen MR; Ditzel HJ
Stem Cells; 2017 Aug; 35(8):1898-1912. PubMed ID: 28600813
[TBL] [Abstract][Full Text] [Related]
37. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
Chen F; Luo N; Hu Y; Li X; Zhang K
Cell Physiol Biochem; 2018; 47(5):2147-2158. PubMed ID: 29975921
[TBL] [Abstract][Full Text] [Related]
38. Soluble CD146 as a Potential Target for Preventing Triple Negative Breast Cancer MDA-MB-231 Cell Growth and Dissemination.
Sharma A; Joshkon A; Ladjimi A; Traboulsi W; Bachelier R; Robert S; Foucault-Bertaud A; Leroyer AS; Bardin N; Somasundaram I; Blot-Chabaud M
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055160
[No Abstract] [Full Text] [Related]
39. Human Primary Breast Cancer Stem Cells Are Characterized by Epithelial-Mesenchymal Plasticity.
Strietz J; Stepputtis SS; Follo M; Bronsert P; Stickeler E; Maurer J
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670400
[TBL] [Abstract][Full Text] [Related]
40. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]